Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Clinical trial NCT02137772 · COMPLETED
Trial details
- NCT number
- NCT02137772
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-06
- Primary completion
- 2016-08-08
- Enrollment
- 570
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.